Silence Therapeutics plc
SLN Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$19.67
KIRA · Stoqly’s AI analyst, in plain words
- Silence Therapeutics plc had $0.6M of revenue in fiscal 2025, down 98.7% on the year before.
- Its operating margin was −16,292.8%, down 16,146.5 pts: of every 100 in sales, about −16,293 is left after running the business.
- Silence Therapeutics plc lost $88.6M in fiscal 2025.
- Free cash flow was −$62.3M in fiscal 2025, −11,149.6% of revenue.
Market cap
$2.8B
P/E
—
Revenue
$0.6M
Net income
−$88.6M
Free cash flow
−$62.3M
Operating margin
−16,292.8%
Silence Therapeutics plc in 30 seconds · fiscal 2025
Are sales growing?
−98.7%
No. Sales fell 98.7% last year.
Does it make a profit?
−15,851.9%
No. It lost money last year.
Does profit turn into cash?
−11,149.6%
No. It spent more cash than it brought in.
How healthy are the accounts?
1 / 8
Weak. It passes 1 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Silence Therapeutics plc does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 5, 2026
- Legal name
- Silence Therapeutics plc
- CIK
- 0001479615
Silence Therapeutics plc · SLN
Results and finances
The last 4 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Sales and profit | ||||
| Revenue | $21.7M | $31.6M | $43.3M | $0.6M |
| Revenue growth | — | 46.1% | 36.7% | −98.7% |
| Gross margin | 37.8% | 59.3% | 72.7% | 61.5% |
| Operating margin | −281.9% | −203.5% | −146.4% | −16,292.8% |
| Net income | −$50.3M | −$54.2M | −$45.3M | −$88.6M |
| Net margin | −232.4% | −171.4% | −104.7% | −15,851.9% |
| Diluted EPS | −$0.52 | −$0.49 | −$0.33 | −$0.63 |
| Cash | ||||
| Cash from operations | −$57.0M | −$49.5M | −$67.6M | −$62.3M |
| Capital expenditure | $0.2M | $0.1M | $0.2M | $0.1M |
| Free cash flow | −$57.2M | −$49.5M | −$67.9M | −$62.3M |
| FCF margin | −264.2% | −156.5% | −156.9% | −11,149.6% |
| Share count change | — | 15.2% | 24.7% | 2.1% |
| Debt and strength | ||||
| Cash and short-term investments | — | $68.8M | $147M | $85.1M |
| Shareholders' equity | $27.2M | $22.0M | $134M | $62.3M |
| Current ratio | — | 4.6x | 11.1x | 8.7x |
| Returns and quality | ||||
| Return on equity | −184.9% | −220.4% | −58.1% | −90.3% |
| Return on tangible equity | −287.0% | −451.4% | −36.4% | −172.4% |
| Piotroski F-score | — | — | 3 | 1 |
| Altman Z'' | — | −10.7 | −2.2 | −12.4 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Silence Therapeutics plc · SLN
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $19.67 a share, the company is worth $2.8B.
Source: SEC EDGAR XBRL filings (CIK 0001479615). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.